Thu, Jul 24, 2014, 9:56 AM EDT - U.S. Markets close in 6 hrs 4 mins

Recent

% | $
Click the to save as a favorite.

MannKind Corp. Message Board

  • howcomethisdoesnotwork howcomethisdoesnotwork Apr 14, 2013 5:47 PM Flag

    Better Subset Based on Trials Possible as Outcome, meeting most end-points

    What if the Technosphere technology works fine, and each patient carries a backup insulin injection pen in the event of a failure, much like the Epi-Pens. This product may be approved for a subset of the population, and as more clinical evidence becomes known over 1-2 years of Phase IV studies, and further research, its customer base expands.
    Maybe there is a way to meet the best of both worlds and reduce or refine the subset of the population that can use this insulin inhaler.
    The share prices could then potentially hit $ 20.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MNKD
9.41-0.150(-1.57%)9:56 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.